PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 18, 2024European Heart Journal85 citationsOpen Access

Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial

View Full Paper
SHStephan von HaehlingWDWolfram DoehnerRERuben Evertz

Key Points

Key points are not available for this paper at this time.

Abstract

Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure with preserved ejection fraction (HFpEF).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Haehling et al. (2024) studied this question.

synapsesocial.com/papers/68e5fc83b6db643587590c98https://doi.org/10.1093/eurheartj/ehae479
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency2009 · 2,086 citations
  2. 2Evolving targets for heart failure: the journey so far2023 · 13 citations
  3. 3Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial2022 · 397 citations
  4. 4Identification of three mechanistic pathways for iron-deficient heart failure2024 · 32 citations
  5. 5Exercise Training Improves Exercise Capacity and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction2011 · 684 citations